|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure显示文摘Hepatocellular carcinoma(HCC) is the main cause of death in patients with cirrhosis, with an increasing incidence worldwide. Sorafenib is the choice therapy for advanced HCC. Over time several randomized phase Ⅲ trials have been performed testing sunitinib, brivanib, linifanib and other molecules in head-tohead comparison with Sorafenib as first-line treatment for advanced-stage HCC, but none of these has so far been registered in this setting. Moreover, another feared vacuum arises from the absence of molecules registered as second-line therapy for patients who have failed Sorafenib, representing an urgent unmet medical need. To date all molecules tested as second-line therapies for advanced hepatocellular carcinoma, failed to demonstrate an increased survival compared to placebo. What are the possible reasons for the failure? What we should expect in the near future? | Marcello Maida Massimo Iavarone Maurizio Raineri Calogero Cammà Giuseppe Cabibbo | 2015 | World Journal of Hepatology2015，7，17： | 7 |
| 2 | Field‐practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy显示文摘 | Massimo Iavarone Giuseppe Cabibbo Fabio Piscaglia Claudio Zavaglia Antonio Grieco Erica Villa Calogero Cammà Massimo Colombo | 2011 | Hepatology2011，，6： | 2 |
| 3 | Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors显示文摘During the last decades,further knowledge of hepatocellular carcinoma(HCC)molecular mechanisms has led to development of effective systemic treatments including tyrosine kinase inhibitors(TKIs)and immunotherapy.In this review,we describe first and second line systemic treatment options for advanced HCC.Several trials have evaluated new drugs for the treatment of HCC patients:In first line,lenvatinib resulted non-inferior to sorafenib and it can be used as alternative,even in the lack of evidence for sequential treatment options in second line after lenvatinib.Recently,atezolizumab plus bevacizumab have shown superiority over sorafenib in first-line.Sorafenib-regorafenib sequential administration in selected patients has opened a new paradigm of treatment in advanced HCC with a life expectancy exceeding two years.Other TKIs for second line treatment include cabozantinib and ramucirumab(specifically for patients with Alpha-fetoprotein values≥400 ng/mL).The combination of TKIs with immunotherapy may represent a big step forward for these patients in the near future. | Federico Pinero Marcelo Silva Massimo Iavarone | 2020 | World Journal of Gastroenterology2020，26，16： | 2 |
| 4 | Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound显示文摘 | Marzia Galassi Massimo Iavarone Sandro Rossi Simona Bota Sara Vavassori Laura Rosa Simona Leoni Laura Venerandi Sara Marinelli Angelo Sangiovanni Letizia Veronese Mirella Fraquelli Alessandro Granito Rita Golfieri Massimo Colombo Luigi Bolondi Fabio Pisca | 2013 | Liver Int2013，，5： | 1 |
| 5 | Characterisation of hepatitis B virus Xproteln mutants in tumor and non-tumor liver cells using laser capture microdissection显示文摘 | Massimo Iavarone Jean-Baptite Trabut | 2003 | Joural of Hepatology2003，39，： | 1 |
| 6 | Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis显示文摘 | Massimo Iavarone Matteo Angelo Manini Angelo Sangiovanni Mirella Fraquelli Laura Virginia Forzenigo Luca Di Tommaso Alessio Aghemo Massimo Roncalli Guido Ronchi Massimo Colombo | 2013 | Digestive and Liver Disease2013，，1： | 1 |
| 7 | Prognostic Gene Expression Signature for Patients With Hepatitis C–Related Early-Stage Cirrhosis显示文摘 | Yujin Hoshida Augusto Villanueva Angelo Sangiovanni Manel Sole Chin Hur Karin L. Andersson Raymond T. Chung Joshua Gould Kensuke Kojima Supriya Gupta Bradley Taylor Andrew Crenshaw Stacey Gabriel Beatriz Minguez Massimo Iavarone Scott L. Friedman Massimo | 2013 | Gastroenterology2013，，5： | 1 |
| 8 | VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE‐1 study显示文摘 | Mario Scartozzi Luca Faloppi Gianluca Svegliati Baroni Cristian Loretelli Fabio Piscaglia Massimo Iavarone Pierluigi Toniutto Giammarco Fava Samuele De Minicis Alessandra Mandolesi Maristella Bianconi Riccardo Giampieri Alessandro Granito Floriana Facchet | 2014 | Int. J. Cancer2014，，： | 1 |
| 9 | Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance显示文摘 | Tommaso Stroffolini Franco Trevisani Giovanbattista Pinzello Franco Brunello Maurizio A. Tommasini Massimo Iavarone Vito Di Marco Fabio Farinati Paolo Del Poggio Franco Borzio Mauro Borzio Eugenio Caturelli Maria Anna Di Nolfo Marta Frigerio Giuseppina Br | 2011 | Digestive and Liver Disease2011，，11： | 1 |
| 10 | Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound显示文摘 | Marzia Galassi Massimo Iavarone Sandro Rossi Simona Bota Sara Vavassori Laura Rosa Simona Leoni Laura Venerandi Sara Marinelli Angelo Sangiovanni Letizia Veronese Mirella Fraquelli Alessandro Granito Rita Golfieri Massimo Colombo Luigi Bolondi Fabio Pisca | 2013 | Liver Int2013，，5： | 1 |
| 11 | The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma显示文摘 | Luca Di Tommaso Annarita Destro Jae Yeon Seok Emanuela Balladore Luigi Terracciano Angelo Sangiovanni Massimo Iavarone Massimo Colombo Ja June Jang Eunsil Yu So Young Jin Emanuela Morenghi Young Nyun Park Massimo Roncalli | 2009 | Journal of Hepatology2009，，4： | 1 |
| 12 | <ce:link locator='fx1'/> Low Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B Patients显示文摘 | Pietro Lampertico Mauro Viganò Elena Manenti Massimo Iavarone Erwin Sablon Massimo Colombo | 2007 | Gastroenterology2007，，5： | 1 |
| 13 | Polymorphism AGT2(rs4762)is involved in the development of dermatologic events:Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib显示文摘BACKGROUND Dermatologic adverse events(DAEs)are associated with a better outcome in patients with hepatocellular carcinoma(HCC)irrespective of the therapeutic agent received.The exact mechanisms associated with the development of DAEs are unknown although several studies point to direct toxicity of tyrosine kinase inhibitors(TKIs)to the skin or an immune-mediated reaction triggered by the oncologic treatment.As is the case in other conditions,individual genetic variants may partially explain a higher risk of DAEs.AIM To evaluate the contribution of several gene variants to the risk of developing DAEs in HCC patients treated with TKIs.METHODS We first analyzed 27 single-nucleotide polymorphisms(SNPs)from 12 genes selected as potential predictors of adverse event(AE)development in HCC patients treated with sorafenib[Barcelona Clinic Liver Cancer 1(BCLC1)cohort].Three additional cohorts were analyzed for AGT1(rs699)and AGT2(rs4762)polymorphisms-initially identified as predictors of DAEs:BCLC2(n=79),Northern Italy(n=221)and Naples(n=69)cohorts,respectively.The relation between SNPs and DAEs and death were assessed by univariate and multivariate Cox regression models,and presented with hazard ratios and their 95%confidence intervals(95%CI).RESULTS The BCLC1 cohort showed that patients with arterial hypertension(AHT)(HR=1.61;P value=0.007)and/or AGT SNPs had an increased risk of DAEs.Thereafter,AGT2(rs4762)AA genotype was found to be linked to a statistically significant increased probability of DAEs(HR=5.97;P value=0.0201,AA vs GG)in the Northern Italy cohort by multivariate analysis adjusted for BCLC stage,ECOG-PS,diabetes and AHT.The value of this genetic marker was externally validated in the cohort combining the BCLC1,BCLC2 and Naples cohorts[HR=3.12(95%CI:1.2-8.14),P value=0.0199,AGT2(rs4762)AA vs AG genotype and HR=2.73(95%CI:1.18-6.32)P value=0.0188,AGT2(rs4762)AA vs GG genotype].None of the other gene variants tested were found to be associated with the risk of DAE development.CONCLUSION DAE development in HCC patients receiving TKIs could be explained by the AGT2(rs4762)gene variant.If validated in other anti-oncogenic treatments,it might be considered a good prognosis marker. | Víctor Sapena Massimo Iavarone Loreto Boix Floriana Facchetti Maria Guarino Marco Sanduzzi Zamparelli Alessandro Granito Esther Samper Mario Scartozzi Josep Corominas Giorgia Marisi Alba Díaz Andrea Casadei-Gardini Laura Gramantieri Pietro Lampertico Filomena Morisco Ferran Torres Jordi Bruix María Reig | 2022 | World Journal of Hepatology2022，14，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员